Skip to main content
. 2022 Dec 29;15(1):216. doi: 10.3390/cancers15010216

Figure 3.

Figure 3

Modification in the tumor microenvironment after the use of imatinib. IM increases the number of NK cells but also supports KIT-dependent crosstalk between DCs and NK cells, resulting in increased production of immune-stimulating IFN-γ. In summary, the inhibition of c-KIT decreases immune-suppressor cells and enhances antitumor immune function [60,61].